IL246614B - (s2)-n-[(s1)-1-cyano-2-phenylethyl]-4,1-oxazapan-2-carboxamides as dipeptidyl peptidase i inhibitors - Google Patents

(s2)-n-[(s1)-1-cyano-2-phenylethyl]-4,1-oxazapan-2-carboxamides as dipeptidyl peptidase i inhibitors

Info

Publication number
IL246614B
IL246614B IL246614A IL24661416A IL246614B IL 246614 B IL246614 B IL 246614B IL 246614 A IL246614 A IL 246614A IL 24661416 A IL24661416 A IL 24661416A IL 246614 B IL246614 B IL 246614B
Authority
IL
Israel
Prior art keywords
oxazepane
carboxamides
phenylethyl
cyano
dipeptidyl peptidase
Prior art date
Application number
IL246614A
Other languages
English (en)
Hebrew (he)
Inventor
Roland Lonn Hans
Connolly Stephen
Swallow Steven
Po Karlsson Staffan
Johan Aurell Carl
Fritiof Ponten John
James Doyle Kevin
Jane Van De Poel Amanda
Peter Jones Graham
Wyn Watson David
Anne Macritchie Jaqueline
John Palmer Nicholas
Original Assignee
Astrazeneca Ab
Roland Lonn Hans
Connolly Stephen
Swallow Steven
Po Karlsson Staffan
Johan Aurell Carl
Fritiof Ponten John
James Doyle Kevin
Jane Van De Poel Amanda
Peter Jones Graham
Wyn Watson David
Anne Macritchie Jaqueline
John Palmer Nicholas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL246614(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Roland Lonn Hans, Connolly Stephen, Swallow Steven, Po Karlsson Staffan, Johan Aurell Carl, Fritiof Ponten John, James Doyle Kevin, Jane Van De Poel Amanda, Peter Jones Graham, Wyn Watson David, Anne Macritchie Jaqueline, John Palmer Nicholas filed Critical Astrazeneca Ab
Publication of IL246614B publication Critical patent/IL246614B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL246614A 2014-01-24 2016-07-05 (s2)-n-[(s1)-1-cyano-2-phenylethyl]-4,1-oxazapan-2-carboxamides as dipeptidyl peptidase i inhibitors IL246614B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
PCT/GB2015/050155 WO2015110826A1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
IL246614B true IL246614B (en) 2018-02-28

Family

ID=52432834

Family Applications (3)

Application Number Title Priority Date Filing Date
IL246614A IL246614B (en) 2014-01-24 2016-07-05 (s2)-n-[(s1)-1-cyano-2-phenylethyl]-4,1-oxazapan-2-carboxamides as dipeptidyl peptidase i inhibitors
IL252836A IL252836A0 (en) 2014-01-24 2017-06-11 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamides as dipeptidyl peptidase i inhibitors
IL265611A IL265611A (en) 2014-01-24 2019-03-25 (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL252836A IL252836A0 (en) 2014-01-24 2017-06-11 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamides as dipeptidyl peptidase i inhibitors
IL265611A IL265611A (en) 2014-01-24 2019-03-25 (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors

Country Status (39)

Country Link
US (18) US9522894B2 (OSRAM)
EP (4) EP4548972A3 (OSRAM)
JP (7) JP6469711B2 (OSRAM)
KR (1) KR102417684B1 (OSRAM)
CN (2) CN110483492B (OSRAM)
AP (1) AP2016009322A0 (OSRAM)
AR (1) AR099177A1 (OSRAM)
AU (4) AU2015208932C1 (OSRAM)
BR (1) BR112016016224B1 (OSRAM)
CA (1) CA2935625C (OSRAM)
CL (1) CL2016001889A1 (OSRAM)
CR (1) CR20160327A (OSRAM)
CY (2) CY1120049T1 (OSRAM)
DK (3) DK3744714T3 (OSRAM)
DO (1) DOP2016000175A (OSRAM)
EA (1) EA032794B1 (OSRAM)
ES (3) ES2658516T3 (OSRAM)
FI (1) FI3744714T3 (OSRAM)
HK (1) HK1225730B (OSRAM)
HR (3) HRP20250302T1 (OSRAM)
HU (3) HUE052421T2 (OSRAM)
IL (3) IL246614B (OSRAM)
LT (3) LT3323814T (OSRAM)
MX (1) MX368840B (OSRAM)
MY (1) MY194850A (OSRAM)
NO (1) NO2699580T3 (OSRAM)
NZ (2) NZ734768A (OSRAM)
PE (1) PE20161218A1 (OSRAM)
PH (1) PH12016501439A1 (OSRAM)
PL (3) PL3323814T3 (OSRAM)
PT (3) PT3744714T (OSRAM)
RS (3) RS56919B1 (OSRAM)
SG (2) SG11201606052TA (OSRAM)
SI (3) SI3097086T1 (OSRAM)
SM (3) SMT201800058T1 (OSRAM)
TW (1) TWI690517B (OSRAM)
UY (1) UY35963A (OSRAM)
WO (1) WO2015110826A1 (OSRAM)
ZA (2) ZA201605856B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (OSRAM) * 2014-01-24 2018-02-24
KR20230054480A (ko) * 2016-07-29 2023-04-24 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR20200118103A (ko) * 2018-02-07 2020-10-14 인스메드 인코포레이티드 Anca 관련 혈관염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
FI3758708T3 (fi) 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
WO2020018551A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
KR20210032431A (ko) * 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
BR112022007623A2 (pt) * 2019-10-23 2022-07-12 Chong Kun Dang Pharmaceutical Corp Composições para prevenir ou tratar doenças pulmonares obstrutivas crônicas (dpoc)
WO2022020245A1 (en) * 2020-07-20 2022-01-27 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
LT4129989T (lt) * 2020-08-26 2024-12-27 Haisco Pharmaceuticals Pte. Ltd. Nitrilo darinys, kuris veikia kaip dipeptidilpeptidazės 1 inhibitorius ir jo panaudojimas
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
CN116157405A (zh) * 2020-12-04 2023-05-23 瑞石生物医药有限公司 组织蛋白酶c小分子抑制剂及其医药用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
AU2022218443B2 (en) * 2021-02-05 2025-03-13 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Fused ring derivatives containing 1,4-oxazepane
CA3215375A1 (en) * 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
JP2024540142A (ja) * 2021-10-29 2024-10-31 インスメッド インコーポレイテッド 慢性副鼻腔炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
WO2023134656A1 (zh) 2022-01-11 2023-07-20 上海壹典医药科技开发有限公司 一种肽基腈类化合物及其应用
MX2024009995A (es) * 2022-02-16 2024-08-22 Insmed Inc Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la hidrosadenitis supurativa.
KR20240153351A (ko) * 2022-02-22 2024-10-22 하이스코 파마수티컬즈 피티이. 엘티디. 디펩티딜 펩티다제 억제제 화합물의 염 및 결정형
CN118696040A (zh) * 2022-02-22 2024-09-24 西藏海思科制药有限公司 一种二肽基肽酶1抑制剂多晶型物及其制备方法和用途
CA3244345A1 (en) 2022-02-22 2025-05-06 Haisco Pharmaceuticals Pte. Ltd. METHOD FOR PREPARING A NITROGENOUS HETEROCYCLIC COMPOUND
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
CN119156391A (zh) 2022-06-07 2024-12-17 瑞石生物医药有限公司 苯并[c]色满化合物的可药用盐、其多晶型及用途
JP2025518342A (ja) * 2022-06-07 2025-06-12 瑞石生物医薬有限公司 ベンゾ［ｃ］クロマン化合物の多形、その製造方法、及びその使用
CN119317620A (zh) 2022-06-13 2025-01-14 亚力维克希斯股份有限公司 氮杂环烷基羰基环状胺化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途
EP4665717A2 (en) * 2023-02-15 2025-12-24 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
WO2024193695A1 (zh) 2023-03-23 2024-09-26 西藏海思科制药有限公司 一种二肽基肽酶小分子抑制剂的药物组合物
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
ATE378411T1 (de) 2000-09-08 2007-11-15 Prozymex As Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
DK1325910T3 (da) 2000-10-06 2008-11-10 Mitsubishi Tanabe Pharma Corp Aliphatiske nitrogenholdige femleddede ringforbindelser
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
BR0214642A (pt) 2001-12-04 2004-11-03 Hoffmann La Roche Compostos, métodos para a preparação de um composto, composições farmacêuticas que compreendem o mesmo e método para o tratamento e/ou prevenção de enfermidades que estão associadas com protéases de cisteìna e utilização desses compostos
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
EP1633702B1 (en) 2003-05-30 2008-07-02 Prozymex A/S Protease inhibitors
US20070099958A1 (en) * 2003-06-18 2007-05-03 Prozymex A/S Protease inhibitors
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US20070286854A1 (en) 2004-04-28 2007-12-13 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
KR100875299B1 (ko) 2004-06-29 2008-12-23 니코메드 덴마크 에이피에스 비수용성 약물의 속방성 약학 조성물 제조 방법 및 상기방법에 의하여 얻어지는 약학 조성물
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
MX383644B (es) 2005-02-18 2025-03-14 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
MX2007015679A (es) 2005-06-30 2008-02-21 Amgen Inc Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer.
US20080221095A1 (en) 2007-03-07 2008-09-11 Christian Gege Metalloprotease inhibitors containing a heterocyclic moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
JP2010540526A (ja) 2007-09-25 2010-12-24 ノバルティス アーゲー エアロゾル化されたバンコマイシンのような薬剤での肺障害の処置
MX2010006110A (es) * 2007-12-12 2010-06-25 Astrazeneca Ab Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i.
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
CN106336400A (zh) 2008-12-08 2017-01-18 萌蒂制药国际有限公司 酪氨酸激酶蛋白受体拮抗剂
KR101824257B1 (ko) 2009-04-01 2018-01-31 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
KR20120034639A (ko) * 2009-05-07 2012-04-12 아스트라제네카 아베 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
AU2012214405B2 (en) 2011-02-11 2015-07-23 Glaxosmithkline Intellectual Property Development Limited Cathepsin C inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
JP6479476B2 (ja) 2012-02-21 2019-03-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類
PT2840083T (pt) 2012-04-17 2017-11-08 Astellas Pharma Inc Composto heterocíclico aromático bicíclico azotado
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
PL2970283T3 (pl) 2013-03-14 2021-05-31 Boehringer Ingelheim International Gmbh Podstawione (benzylocyjanometylo)amidy kwasu 2-aza-bicyklo[2.2.1]heptano-3-karboksylowego będące inhibitorami katepsyny c
EP2970230B1 (en) 2013-03-14 2019-05-22 Boehringer Ingelheim International GmbH Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US8877775B2 (en) 2013-03-14 2014-11-04 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
EP2970228B1 (en) 2013-03-14 2017-05-10 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
HK1221175A1 (zh) 2013-04-01 2017-05-26 Pulmatrix Operating Company, Inc. 噻托溴铵乾粉
US10670594B2 (en) 2013-08-22 2020-06-02 Emory University Devices and methods related to airway inflammation
EA029030B1 (ru) 2013-09-09 2018-01-31 Прозюмекс А/С Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (OSRAM) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
TW201622721A (zh) 2014-04-10 2016-07-01 諾華公司 Ｓ１ｐ調節劑之立即釋放劑量療法
MX376012B (es) 2014-05-15 2025-03-07 Insmed Inc Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
EP3149192B1 (en) 2014-05-30 2019-01-02 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
JP2017526716A (ja) 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃのスピロ環状阻害剤
AU2015345070A1 (en) 2014-11-14 2017-04-20 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists
EP3265452B1 (en) 2015-03-05 2020-03-04 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
KR20230054480A (ko) 2016-07-29 2023-04-24 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR20200118103A (ko) 2018-02-07 2020-10-14 인스메드 인코포레이티드 Anca 관련 혈관염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
FI3758708T3 (fi) 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
WO2020018551A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
WO2020214855A1 (en) 2019-04-17 2020-10-22 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
WO2020247665A1 (en) 2019-06-05 2020-12-10 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
CA3215375A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
JP2024540142A (ja) 2021-10-29 2024-10-31 インスメッド インコーポレイテッド 慢性副鼻腔炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
MX2024009995A (es) 2022-02-16 2024-08-22 Insmed Inc Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la hidrosadenitis supurativa.

Also Published As

Publication number Publication date
US20210238152A1 (en) 2021-08-05
US20240336582A1 (en) 2024-10-10
MX2016009349A (es) 2016-10-13
AU2019202675A1 (en) 2019-05-16
RS66709B1 (sr) 2025-05-30
LT3097086T (lt) 2018-02-26
HRP20180116T1 (hr) 2018-03-23
CR20160327A (es) 2016-10-20
US20240132455A1 (en) 2024-04-25
AU2017200338A1 (en) 2017-02-02
US20230116721A1 (en) 2023-04-13
CN110483492B (zh) 2023-07-21
US11673872B2 (en) 2023-06-13
SMT201800058T1 (it) 2018-03-08
CA2935625A1 (en) 2015-07-30
PH12016501439B1 (en) 2017-02-06
US11673871B2 (en) 2023-06-13
US11814359B2 (en) 2023-11-14
KR102417684B1 (ko) 2022-07-05
DK3097086T3 (en) 2018-02-05
SMT202000433T1 (it) 2020-09-10
US11680049B2 (en) 2023-06-20
US11667615B2 (en) 2023-06-06
AU2018202956B2 (en) 2019-05-09
BR112016016224B1 (pt) 2023-02-23
JP2023156479A (ja) 2023-10-24
TW201612167A (en) 2016-04-01
HUE052421T2 (hu) 2021-04-28
AU2015208932A1 (en) 2016-07-28
US20230250071A1 (en) 2023-08-10
LT3744714T (lt) 2025-04-10
PT3323814T (pt) 2020-08-05
JP2021046423A (ja) 2021-03-25
DK3323814T3 (da) 2020-08-03
TWI690517B (zh) 2020-04-11
JP2022096662A (ja) 2022-06-29
PL3097086T3 (pl) 2018-04-30
BR112016016224A2 (OSRAM) 2017-08-08
JP2017503832A (ja) 2017-02-02
JP2019070029A (ja) 2019-05-09
SI3744714T1 (sl) 2025-05-30
US20230069044A1 (en) 2023-03-02
NO2699580T3 (OSRAM) 2018-02-24
MX368840B (es) 2019-10-18
CN110483492A (zh) 2019-11-22
US11655223B2 (en) 2023-05-23
IL265611A (en) 2019-05-30
HUE070606T2 (hu) 2025-06-28
JP7336563B2 (ja) 2023-08-31
ES2658516T3 (es) 2018-03-12
CL2016001889A1 (es) 2016-12-09
AR099177A1 (es) 2016-07-06
US20230025351A1 (en) 2023-01-26
AU2019202675B2 (en) 2020-05-28
AU2015208932A8 (en) 2017-03-09
US20230085620A1 (en) 2023-03-23
CN105980367B (zh) 2019-08-23
SMT202500137T1 (it) 2025-05-12
DK3744714T3 (da) 2025-04-07
EP3323814B1 (en) 2020-05-13
EP4548972A2 (en) 2025-05-07
AU2015208932B2 (en) 2017-02-16
ES3018635T3 (es) 2025-05-16
JP7714823B2 (ja) 2025-07-29
ZA201800431B (en) 2019-09-25
HK1255870A1 (en) 2019-08-30
JP2025072423A (ja) 2025-05-09
US20230062646A1 (en) 2023-03-02
US12054465B2 (en) 2024-08-06
HUE038274T2 (hu) 2018-10-29
US11117874B2 (en) 2021-09-14
EP3097086A1 (en) 2016-11-30
US20230278969A1 (en) 2023-09-07
CY1120049T1 (el) 2018-12-12
AU2015208932B8 (en) 2017-03-09
CA2935625C (en) 2022-10-18
LT3323814T (lt) 2020-10-26
KR20160111470A (ko) 2016-09-26
EP3744714B1 (en) 2025-01-15
CY1123391T1 (el) 2021-12-31
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
US11655224B2 (en) 2023-05-23
US20180251436A1 (en) 2018-09-06
PL3323814T3 (pl) 2020-10-19
EP3744714A1 (en) 2020-12-02
HRP20250302T1 (hr) 2025-04-25
EP3323814A1 (en) 2018-05-23
NZ734768A (en) 2022-09-30
US20150210655A1 (en) 2015-07-30
US11655221B2 (en) 2023-05-23
US20230028726A1 (en) 2023-01-26
EP4548972A3 (en) 2025-06-25
EA201691375A1 (ru) 2017-01-30
US20230033573A1 (en) 2023-02-02
PE20161218A1 (es) 2016-11-27
EP3097086B1 (en) 2017-12-13
PL3744714T3 (pl) 2025-09-08
DOP2016000175A (es) 2016-08-15
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
US11655222B2 (en) 2023-05-23
US10669245B2 (en) 2020-06-02
PH12016501439A1 (en) 2017-02-06
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
ZA201605856B (en) 2020-02-26
AU2015208932C1 (en) 2017-05-25
US10287258B2 (en) 2019-05-14
IL252836A0 (en) 2017-08-31
PT3744714T (pt) 2025-04-07
HK1225730B (en) 2017-09-15
JP7628587B2 (ja) 2025-02-10
CN105980367A (zh) 2016-09-28
SI3323814T1 (sl) 2020-10-30
US20200017455A1 (en) 2020-01-16
SI3097086T1 (en) 2018-04-30
JP6804570B2 (ja) 2020-12-23
JP2025157389A (ja) 2025-10-15
AU2017200338B2 (en) 2018-03-01
SG10201701056QA (en) 2017-03-30
MY194850A (en) 2022-12-19
JP7157791B2 (ja) 2022-10-20
US20200247765A1 (en) 2020-08-06
AU2018202956A1 (en) 2018-05-17
US9522894B2 (en) 2016-12-20
NZ722063A (en) 2017-09-29
AP2016009322A0 (en) 2016-07-31
JP6469711B2 (ja) 2019-02-13
EA032794B1 (ru) 2019-07-31
HRP20201147T1 (hr) 2020-12-11
US20230115170A1 (en) 2023-04-13
US20170057938A1 (en) 2017-03-02
US9815805B2 (en) 2017-11-14
RS60639B1 (sr) 2020-09-30
WO2015110826A1 (en) 2015-07-30
SG11201606052TA (en) 2016-08-30

Similar Documents

Publication Publication Date Title
IL265611A (en) (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
DK3265452T3 (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
IL256347A (en) New thrombin inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed